INCYTE CORP (INCY) Stock News
NASDAQ:INCY - Nasdaq - US45337C1027 - Common Stock - Currency: USD
INCY Latest News, Press Relases and Analysis
Discover the top S&P500 movers in Tuesday's after-hours session.
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.
Tuesday's pre-market session: top gainers and losers in the S&P500 index
The US market session of Tuesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.
Incyte to Present at Upcoming Investor Conference
Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday?
Wall Street modestly up as investors await economic data and corporate earnings. Bond market continues rally, gold and oil prices fall.Wall Street rises modestly, bond market continues rally, gold and oil prices fall as investors await economic data and corporate earnings.
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings
The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
3 Value Stocks Facing Headwinds
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit of $1.16 per share was 10.6% above analysts’ consensus estimates.
NICE Lowered Revenue Outlook But Bullish Analyst Sees AI Momentum And Strong Cash Flow
Rosenblatt analyst Catharine Trebnick maintained NICE Ltd (NASDAQ:NICE) with a Buy rating and lowered the price forecast from $200 to $180 Thursday. Trebnick lowered her price forecast due to reduced fiscal 2025 and 2026 revenue estimates, citing macroeconomic uncertainty, which could further delay multinational Contact Center as a Service (CCaaS) deployments. The price target reflects ~3.4 times (from ~4 times) on the analyst’s revenue estimate of 7% Y/ Y in fiscal 2026. Also Read: Five9 Leans
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: BPMC
Blueprint Medicines Corporation (BPMC): Among Takeover Rumors Hedge Funds Are Buying
We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain […]
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying.
Take a closer look at INCYTE CORP , a remarkable value stock. NASDAQ:INCY excels in fundamentals and maintains a very reasonable valuation.
Incyte to Report First Quarter Financial Results
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
